# US 2013/0157965 A1 · Prevention and Treatment of Oxidative Stress Disorders by Glutathione and Phase II Detoxification Enzymes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0157965 A1
- Document ID: US20130157965A1
- Status: Published application
- Kind: A1
- Application number: 13/670,161
- Filed: 2012-11-06
- Published: 2013-06-20
- Earliest claimed: 2001-12-18
- Assignees: Brassica Foundation for Chemoprotection Research, Inc.
- Inventors: Xiangqun GAO; Albena T. DINKOVA-KOSTOVA; Paul TALALAY
- Web page: https://patentgrep.com/patent/US20130157965A1

## CPC

- A61K 31/7024: Esters of saccharides
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/26: Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
- A61P 17/18: Antioxidants, e.g. antiradicals (preparations for protection against sunlight A61Q17/00)
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 39/06: Free radical scavengers or antioxidants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention generally relates to the field of treating oxidative stress disorders by administering a pharmaceutically effective amount of a compound that elevates the intracellular levels of glutathone or intracelluar levels of at least one Phase II detoxification enzyme in animal tissue. The present invention also relates to the field of protecting a subject from oxidative stress disorders by administering a pharmaceutically effective amount of a compound that elevates the intracellular levels of glutathone or intracelluar levels of at least one Phase II detoxification enzyme in the subject. The present invention also relates to a pharmaceutical composition useful for the treatment of oxidative stress disorders.

## Claims

### Claim 1

A method of treating a subject in need of treatment of an oxidative stress disorder, said method comprising administering to said subject a composition comprising a pharmaceutically effective amount of a compound that elevates intracellular levels of glutathione or intracelluar levels of at least one Phase IT detoxification enzyme in diseased tissue of said subject, wherein said oxidative stress disorder is selected from the group consisting of Alzheimer's Disease and aging.

### Claim 2 (depends on 1)

The method of claim 1, wherein said compound is selected from the group consisting of an isothiocyanate and a glucosinolate.

### Claim 3 (depends on 2)

The method of claim 2, wherein said isothiocyante is sulforaphane.

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The method of claim 1, wherein said Phase IT detoxification enzyme is selected from the group consisting of UDP-glucuronosyltransferases, sulfotransferases, phenol-O-methyltransferase, catechol-O-methyltransferase, histamine N-methyltransferase, nicotinamide N-methyltransferase, thiopurine methyltransferase, thiol methyltransferase, N-acetyltransferases, O-acetyltransferases, acyl-CoA synthetases, acyl-CoA:amino acid N-acyltransferases, aminoacyl-tRNA synthetases, glutathione synthetases, gamma glutamylcysteine synthetases, glutathione S-transferases, quinone reductases, heme oxygenases, rhodaneses, glutathione reductase, glutathione peroxidase, catalase and superoxide dismutase.

### Claim 6

A method of protecting a subject from an oxidative stress disorder, said method comprising administering to said subject a composition comprising a pharmaceutically effective amount of a compound that elevates intracellular levels of glutathione or intracellular levels of at least one Phase II detoxification enzyme in diseased tissue of said subject, wherein said oxidative stress disorder is selected from the group consisting of Alzheimer's Disease and aging.

### Claim 7 (depends on 6)

The method of claim 6, wherein said compound is selected from the group consisting of an isothiocyanate and a glucosinolate.

### Claim 8 (depends on 7)

The method of claim 7, wherein said isothiocyante is sulforaphane.

### Claim 9

(canceled)

### Claim 10 (depends on 6)

The method of claim 6, wherein said Phase II detoxification enzyme is selected from the group consisting of UDP-glucuronosyltransferases, sulfotransferases, phenol-O-methyltransferase, catechol-O-methyltransferase, histamine N-methyltransferase, nicotinamide N-methyltransferase, thiopurine methyltransferase, thiol methyltransferase, N-acetyltransferases, O-acetyltransferases, acyl-CoA synthetases, acyl-CoA:amino acid N-acyltransferases, aminoacyl-tRNA synthetases, glutathione synthetases, gamma glutamylcysteine synthetases, glutathione S-transferases, quinone reductases, heme oxygenases, rhodaneses, glutathione reductase, glutathione peroxidase, catalase and superoxide dismutase.

### Claim at position 11

-29. (canceled)

### Claim 30 (depends on 1)

The method of claim 1, wherein the composition is administered orally, nasally, parenterally, intrasystemically, intraperitoneally, topically, bucally, or as an oral or nasal spray.

### Claim 31 (depends on 1)

The method of claim 1, wherein the composition further comprises a carrier or excipient and is formulated as a lotion, a cream, a gel or an ointment for topical administration.

### Claim 32 (depends on 31)

The method of claim 31, wherein the composition is administered to the skin.

### Claim 33 (depends on 6)

The method of claim 6, wherein the composition is administered orally, nasally, parenterally, intrasystemically, intraperitoneally, topically, bucally, or as an oral or nasal spray.

### Claim 34 (depends on 6)

The method of claim 6, wherein the composition further comprises a carrier or excipient and is formulated as a lotion, a cream, a gel or an ointment for topical administration.

### Claim 35 (depends on 34)

The method of claim 34, wherein the composition is administered to the skin.
